Artax Biopharma is a biopharmaceutical company that develops new therapies for autoimmune and inflammatory diseases.
Artax Biopharma has raised $8.0M in total funding. The most recent round was Convertible Note. The last funding was announced in August 2024.
Artax Biopharma's investors include Eli Lilly, Columbus Venture Partners, Sound Bioventures, Eli Lilly & Company Foundation, Advent Life Sciences.
Artax Biopharma is headquartered in Cambridge, United States.
Artax Biopharma is a biopharmaceutical company that develops new therapies for autoimmune and inflammatory diseases.
Artax Biopharma is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Artax Biopharma — Funding & Investors." VCBacked, August 6, 2024, https://www.vcbacked.co/company/artax-biopharma. Accessed August 14, 2026.
VCBacked. (2024). Artax Biopharma — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/artax-biopharma
{{cite web |title=Artax Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/artax-biopharma |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated